Karen Andrews, MD
Allergy · Boulder, CONPI 1750365565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Sanofi at 54.1% of the total.
Across 4 payments — averaging $33.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$71
- ARS Pharmaceuticals Operations, Inc.$42
- QOL Medical, LLC$18
What the payments were for
- Food & beverage$132100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $71 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $42 |
| QOL Medical, LLC | 1 | $18 |
How this compares
Too few allergy providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 73 | $297,478 |
| XolairOmalizumab | 41 | $121,771 |
| Dupixent PenDupilumab | 11 | $43,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $42,365 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $31,588 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,466 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,435 |
| DuleraMometasone/Formoterol | 21 | $8,496 |
| Epinephrine | 33 | $7,613 |
| Cromolyn Sodium | 23 | $4,720 |
| Serevent DiskusSalmeterol Xinafoate | 11 | $4,536 |
| QnaslBeclomethasone Dipropionate | 13 | $4,045 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,931 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $1,211 |
| Diphenhydramine Hcl | 29 | $1,062 |
Paid to pharmacies, not to this prescriber.
Other allergy in Boulder
- Mark MenichBoulder$132
- Nathanael BradyColorado Springs$971K
- Mark BoguniewiczDenver$814K
- Daniel SoteresColorado Springs$650K
- Regan PyleAvon$72K
- William LantingFort Collins$36K
- Christianne McGrathColorado Springs$11K
- Carmen LaronnCentennial$844
- William SilversCentennial$160
- Kirstin CarelAurora$36
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.